Cell Line & Expression Development
Cell line and expression development are critical first steps in biologics CMC development, directly influencing product quality, manufacturing efficiency, scalability, and long-term commercial success. A robust expression platform enables reliable production of high-quality recombinant proteins while minimizing development risks and shortening timelines. At Protheragen, we provide integrated cell line & expression development services that support every stage of early biologics development. From manufacturability assessment and rapid transient protein expression to stable cell line generation, our experienced scientists work closely with clients to establish optimized production platforms tailored to each molecule and development strategy.
Overview of Cell Line & Expression Development
Cell line and expression development encompass a series of critical technologies used to evaluate biologic candidates, establish efficient expression systems, and generate stable production cell lines for therapeutic protein manufacturing. These technologies bridge early-stage research and downstream process development by ensuring that selected candidates possess favorable manufacturability, robust expression performance, and consistent product quality.
A typical development strategy begins with manufacturability assessment to evaluate molecular characteristics, stability, and developability of candidate molecules. Transient transfection is then applied to rapidly express recombinant proteins for early functional evaluation and process feasibility studies. Once lead candidates are selected, stable cell line development enables the generation of genetically stable, high-producing cell lines suitable for process optimization, clinical manufacturing, and commercial production.
Fig.1 Current focus areas of innovative research in industrial cell line development. (Borbála T, et al., 2020)
Our Services
01
Manufacturability Assessment
Evaluate the developability of biologic candidates through comprehensive assessments of post-translational modifications (PTMs), physicochemical properties, and molecular stability. Early identification of molecular liabilities helps prioritize lead candidates, reduce CMC risks, and establish a solid foundation for downstream development.
02
Transient Transfection Services
Rapidly generate high-quality recombinant proteins using optimized mammalian transient expression platforms for candidate screening, functional studies, and early process development.
03
Cell Line Development
Develop stable, high-producing production cell lines with excellent genetic stability and consistent product quality for seamless transition into process development and GMP manufacturing.
Supported Molecules
Our Cell Line & Expression Development platform supports the development of a broad range of biologics, including:
- Monoclonal antibodies (mAbs)
- Bispecific antibodies
- Recombinant proteins
- Fc-fusion proteins
- Antibody fragments
- Cytokines
- Enzymes
- Biosimilars
- Other recombinant biologics
Technology Platform
Our integrated technology platform combines comprehensive developability evaluation, advanced mammalian expression systems, and stable cell line engineering to support every stage of biologics development, from early candidate assessment to scalable production.
| Technology Platform |
Capabilities & Applications |
| Manufacturability Assessment |
Developability evaluation, PTM analysis, physicochemical characterization, molecular stability assessment |
| Mammalian Transient Expression |
Rapid recombinant protein production using HEK293 and CHO transient expression systems |
| Stable Cell Line Development |
Stable pool generation, single-cell cloning, clone screening, cell banking |
| Cell Characterization |
Productivity, genetic stability, clone identity, product quality evaluation |
Why Choose Protheragen
1. Integrated Development Platform
A seamless workflow from candidate evaluation through stable cell line generation accelerates biologics development and minimizes technology transfer risks.
2. Optimized Mammalian Expression Systems
Multiple mammalian host cell platforms provide flexible solutions for a wide range of recombinant biologics.
3. High Productivity and Stability
Our optimized development strategies consistently generate high-producing, genetically stable cell lines with reliable product quality.
4. High-Throughput Screening Technologies
Advanced screening platforms accelerate clone identification while ensuring optimal productivity and critical quality attributes.
5. Scalable Manufacturing Compatibility
Cell lines are developed using suspension culture systems compatible with laboratory, pilot, clinical, and commercial manufacturing.
6. Experienced Scientific Expertise
Our multidisciplinary team combines expertise in molecular biology, cell engineering, process development, and analytical sciences to deliver customized solutions for every project.
Successful biologics development begins with a robust expression platform and a reliable production cell line. Protheragen's integrated cell line & expression development services combine scientific expertise, advanced technologies, and scalable development strategies to help clients efficiently move from candidate evaluation to manufacturing-ready cell lines. By reducing technical risks and optimizing development workflows, we provide a strong foundation for successful clinical and commercial biologics manufacturing. Contact us to discuss your project and discover how our integrated CDM O solutions can support your project from early discovery through commercial manufacturing.
Reference
- Borbála T, et al. "Recent advances in CHO cell line development for recombinant protein production" Drug Discovery Today: Technologies, 2020, 38: 25-34.
